B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKAA1

MOLECULAR TARGET

protein kinase AMP-activated catalytic subunit alpha 1

UniProt: Q13131NCBI Gene: 556211 compounds

PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKAA1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Adenosine Monophosphate Adenine nucleotide containing2.087
2Proguanil1.956
3Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone1.614
4Niclosamide1.393
5Ursolic Acid1.102
6Antimycin1.102
7Oleanolic Acid1.102
8Rotenone1.102
9Berberine0.691
10Metformin0.691
11Crizotinib0.691

About PRKAA1 as a Drug Target

PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented PRKAA1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKAA1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.